With strong international collaborations, ICPO has built a worldwide network of over 50 Clinical Theranostics Centers of Excellence
January 28, 2026 – Wiesbaden, Germany. The International Centers for Precision Oncology (ICPO) Foundation today published its first Impact Report. 2025 was a breakthrough year for ICPO, emerging as a truly global non-profit player in Theranostics. The foundation has made meaningful progress for cancer patients worldwide, focusing on improved patient access to Theranostics and better clinical outcomes. Supporting Theranostics centers globally, it enhances clinical practice, accelerates education, and fosters innovation. ICPO has developed a unique strategy that takes into account regional and national realities and the different maturity levels of Theranostics centers. This approach is further strengthened by strong partnerships with leading medical societies, scientific experts, non-profit organizations, patient associations, governmental agencies, and industry leaders. In 2025, ICPO significantly expanded its international network of Clinical Theranostics Centers of Excellence (CoE), growing from 11 centers in 2024 to over 50 in 2025, with the aim to double this number in 2026. To further amplify its mission, ICPO became a co-founding member of the RLT Angels Association in 2025, alongside the European Association of Nuclear Medicine (EANM) and industry partners GE Healthcare, Novartis, and RayzeBio, a Bristol Myers Squibb company.
Cancer remains one of the world’s most pressing health challenges, and patients need more effective, personalized treatments. Theranostics integrates diagnostic imaging with targeted radiopharmaceutical therapy, enabling more precise treatment and improved clinical outcomes. Pivotal trials have demonstrated that certain radiopharmaceuticals have a favorable benefit-risk profile in advanced neuroendocrine tumors and metastatic prostate cancer.[1]1 In major EU countries and the UK only, required treatment slots are projected to rise from about 150,000 in 2025 to 500,000 in 2033 – nearly a five-fold increase.2 With EMA and FDA approvals expanding patient access to Theranostics, the path is now open for advancing and registering radiopharmaceutical treatments for more cancer indications.3
Sen. h.c. Udo J. Vetter, Chairman of the Board of Trustees, emphasized the significant progress achieved by the ICPO Foundation, stating: “ICPO’s development in 2025 demonstrates the value of combining scientific excellence with strong global partnerships. As demand for Theranostics continues to grow, ICPO is expanding access, driving innovation, and supporting high standards of care to achieve better patient outcomes worldwide.”
Reflecting on the ICPO Foundation´s achievements, Odile Jaume, CEO of the ICPO Foundation, highlighted: “With the expansion of our global network of Clinical Theranostics Centers of Excellence, we moved decisively from vision to impact. By strengthening clinical practice and accelerating education worldwide, we are helping ensure that more cancer patients benefit from precise, personalized treatments with Theranostics – regardless of geography.”
Building ICPO Global Centers of Excellence Network
With the aspiration of treating 1 million patients worldwide with high standards of care, ICPO is building a strong network of ICPO Clinical Theranostics Centers of Excellence, which reached over 50 centers in 2025. The foundation offers a structured accreditation pathway that recognizes centers‘ current achievements and provides a clear roadmap for future development. Whether a center is newly established or already a global leader, this framework ensures adequate support at every stage, enhancing growth and strengthening expertise in Theranostics. By joining the network, centers benefit from an accreditation scheme aligned with international standards and shared values from the world‘s leading scientific societies.
Educating Next Generation Theranostics Experts
Certified continued medical education in Theranostics is rooted in the mission of the ICPO Foundation. In 2025, the ICPO Academy for Theranostics reached 800 alumni from more than 30 countries and incorporated new languages, including German, Korean, and Japanese, offering the lectures in 10 languages. Accredited by the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), the ICPO Academy for Theranostics has been endorsed by 11 international nuclear medicine societies and features the International Atomic Energy Agency (IAEA) as a cooperation partner. The next level of the e-learning program, under development, will comprise clinical cases and multidisciplinary tumor boards that illustrate real-world medical scenarios from various regions of the world.
Advancing Scientific Innovation through ICPO Research Grants
ICPO receives essential scientific and medical guidance across all ICPO activities from its world-class Scientific Advisory Board (SAB), chaired by Prof. Richard P. Baum, with Prof. Frederik L. Giesel appointed Co-Chair in December 2025. The SAB also comprises 17 internationally recognized experts from 9 countries.
The foundation is committed to empowering scientific talents and celebrating contributions that truly shape the field of Theranostics. Since 2019, ICPO has funded EUR 1.6 million in research grants, including EUR 225,000 in 2025 due to generous donations from patients. A new call for applications was launched in 2025 to accelerate the use of AI in Theranostics, particularly through standardized imaging and therapy datasets. Furthermore, ICPO recognizes groundbreaking research in Actinium-225 radiopharmaceutical science through the “Maurits W. Geerlings Next Generation Award”. In January 2026, the newly created “Scott Smallwood Honor for Lifetime Achievement in Theranostics” will be presented for the first time at the Theranostics World Congress 2026 in Cape Town, South Africa, recognizing outstanding lifetime contributions and dedication to the field of Theranostics.
Fostering cooperations with international partners
Partnerships are crucial to maximizing the impact of ICPO’s mission. In line with this, ICPO joined the RLT Angels Association as a co-founder alongside EANM and industry partners GE Healthcare, Novartis, and RayzeBio, a BMS company. The RLT Angels Association is a public-private partnership, where members advocate collectively for better patient outcomes and aim for large-scale targets such as 1 million patients treated in 1000 centers. All ICPO initiatives contribute to this collective effort and, in return, benefit from it.
Developing a global ICPO Community with all Theranostics stakeholders
At the heart of ICPO’s mission is a strong, inclusive global community dedicated to advancing Theranostics, uniting clinicians, researchers, industry leaders, nonprofit associations, and scientific societies. Through knowledge exchange and international collaboration, ICPO fosters excellence and works toward improved patient outcomes worldwide. Therefore, the ICPO Foundation hosts two flagship events: the ICPO Theranostics Virtual Summit – attended by more than 400 participants in 2024 and scheduled to take place again on November 12–13, 2026 – and the ICPO Forum for Theranostics in Precision Oncology, an in-person event organized at the TUM Campus in Garching near Munich, which in 2025 gathered over 240 attendees.
Photos captions:
Cover photo: Impact Report 2025 of the International Centers of Precision Oncology (ICPO) Foundation. On request available: Impact Report 2025 – Key Facts & Figures of the ICPO Foundation and Global Map of ICPO Clinical Theranostics Centers of Excellence
About ICPO Foundation
The International Centers for Precision Oncology Foundation (ICPO) is a non-profit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a paradigm shift in cancer care to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access by developing an international network of physical diagnostic and therapeutic centers for Precision Oncology based on a model of shared know-how, certified education with the ICPO Academy for Theranostics, and design and process standardization that enables best clinical practice for improved patient outcomes globally. www.icpo.foundation
Learn more about the ICPO Foundation at www.icpo.foundation and the ICPO Academy for Theranostics at www.theranostics.academy
Media contact ICPO Foundation
Susanne Simon, Head of Communication & Community
Email: susanne.simon@icpo.foundation, Phone: + 49 172 8666093, www.icpo.foundation
[1]-3 “Are European Healthcare Systems Prepared for a Potential Rapid Rise in Radioligand Therapy Eligible Patient Numbers?”, Leonhard Schaetz, Margarida Goulart, Roberta Cirillo, Diego Hernandez, Platon Peristeris, Andreas Poschenrieder, Panagiota Papaioannou, Panos Kanavo, Christian la Fougère, Uwe Holzwarth, et al. Poster presented at ESMO Congress 2025, October 2025.